about
The feasibility of using technology to enhance the transition of palliative care for rural patients.Tracking Discharge Delays: Critical First Step Toward Mitigating Process Breakdowns and Inefficiencies.Ethical Considerations Related to Return of Results from Genomic Medicine Projects: The eMERGE Network (Phase III) Experience.Primary care physicians' perceptions of practice improvement as a professional responsibility: a cross-sectional study.The Return of Actionable Variants Empirical (RAVE) Study, a Mayo Clinic Genomic Medicine Implementation Study: Design and Initial ResultsThe comparative effectiveness of decision aids in diverse populations with early stage prostate cancer: a study protocol for a cluster-randomized controlled trial in the NCI Community Oncology Research Program (NCORP), Alliance A191402CDShould pretest genetic counselling be required for patients pursuing genomic sequencing? Results from a survey of participants in a large genomic implementation studyAssessing optimism and pessimism about genomic medicine: Development of a genomic orientation scaleManaging the Unimaginable: Biobank Participant Views on Reconsent for Whole Genome Sequencing of Stored BiospecimensExamining Physician Interactions with Disease Advocacy OrganizationsCharacteristics and Scope of Training of Clinicians Participating in the US Direct-to-Consumer Marketplace for Unproven Stem Cell InterventionsUS Physicians' Reactions To ACA Implementation, 2012-17Assessing the stability of biobank donor preferences regarding sample use: evidence supporting the value of dynamic consentChallenges in returning results in a genomic medicine implementation study: the Return of Actionable Variants Empirical (RAVE) study
P50
Q40190261-712EFBB0-B9BB-43A0-A1B4-2A0C78CFB2ACQ40746195-321F73A3-42A6-4C93-926E-F292A7E8BA1CQ50119980-FE90BF70-FE6F-4013-B628-0A9C1001E2ECQ55034269-2D26828C-B24F-4DDD-ADF6-EC0F3D19D98BQ58566739-9D465DF4-558B-4298-8B63-9C1F3782448AQ58799382-7498959B-A4F4-4BAA-87E0-9274E2C08962Q90722853-8D2408C4-939F-4969-8B37-C4DE7299D298Q92347447-498442BE-158A-4D19-9842-7CC8B96F1A9EQ92624355-8FA251A3-FEDA-4E4C-83A3-CF75DEE37A5AQ92866917-5F4103FD-474A-434B-8130-089C1C873D7CQ93011866-AB6E132A-C9F4-4512-89C0-B6A172A310B6Q93073433-2BE1F5B2-CFFF-4878-93B4-0EB4A3B825C3Q93196132-FF9E15E0-962F-4688-AEAF-F3D843E199CEQ94595312-83A591BA-91DC-4B39-8116-A0FD61409E6E
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Joel E Pacyna
@ast
Joel E Pacyna
@en
Joel E Pacyna
@es
Joel E Pacyna
@nl
Joel E Pacyna
@sl
type
label
Joel E Pacyna
@ast
Joel E Pacyna
@en
Joel E Pacyna
@es
Joel E Pacyna
@nl
Joel E Pacyna
@sl
prefLabel
Joel E Pacyna
@ast
Joel E Pacyna
@en
Joel E Pacyna
@es
Joel E Pacyna
@nl
Joel E Pacyna
@sl
P106
P108
P21
P31
P496
0000-0002-3103-7805